Level D· Scientific groundwork from lab and animal studiesAnimal StudyPubMed

Injection of basic fibroblast growth factor together with adipose-derived stem cell transplantation: improved cardiac remodeling and function in myocardial infarction.

Wang B., Ma X., Zhao L., Zhou X., Ma Y., Sun H.

Animal Study on Cardiovascular Disease, published in Clin Exp Med (2015) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
Clin Exp Med (2015)
Country
Italy
Reported sample size
—
Source database
PubMed
PMID
26349680
DOI
10.1007/s10238-015-0383-0
Citations
14

Abstract (original English)

Recent findings suggest that cell and gene transplantation in the infarcted myocardium may improve heart function. The aim of the study was to investigate the mechanism involved in improving heart function following the co-injection of adipose-derived stem cells (ADSCs) and basic fibroblast growth factor (bFGF) in a rat model of myocardial infarction. In this study, ADSCs were isolated from subcutaneous adipose tissues. The ADSCs were induced to differentiate into adipocytes, osteoblasts and cardiac myocytes in vitro. bFGF was co-injected with the ADSCs into the left ventricular wall in a rat myocardial infarction model. The structural and functional outcomes resulting from this transplantation were determined through detailed histological analysis and echocardiography. The graft size was significantly larger in the bFGF + ADSC group than in the PBS + ADSC group and PBS + bFGF group 4 weeks after injection (p < 0.05). The ADSCs were able to differentiate into cardiomyocytes, endothelial cells and vascular smooth muscle cells in vivo. There was a significant improvement in arteriole density within the infarcted area in the bFGF + ADSC group compared with the PBS + ADSC group and the PBS + bFGF group 4 weeks after transplantation (p < 0.05). The results of Western blot analysis showed that all of the treatments significantly reduced MMP2 and MMP9 protein levels compared with the

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
Adipose TissueAnimalsAtrial RemodelingCell DifferentiationCells, CulturedCombined Modality TherapyDisease Models, AnimalFemaleFibroblast Growth Factor 2Heart Function Tests

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research